Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis
Kelly J. Norsworthy(United States Food and Drug Administration), David J. Graham(United States Food and Drug Administration), Gideon M. Blumenthal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Meredith K. Chuk(Center for Drug Evaluation and Research), Michael Wernecke(Acumen (United States)), Jiemin Liao(National University of Singapore), Thomas MaCurdy(Acumen (United States)), Richard Pazdur(United States Food and Drug Administration), Armen Avagyan(Acumen (United States)), Sandia Akhtar(Acumen (United States)), Steven T. Bird(United States Food and Drug Administration), Ann T. Farrell(Center for Drug Evaluation and Research), Yuchen Li(University of California San Diego), Jeffrey A. Kelman(Centers for Medicare and Medicaid Services), Richard S. Swain(United States Food and Drug Administration), Albert Deisseroth(National Cancer Institute), R. Angelo de Claro(United States Food and Drug Administration)
Cited by 32
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k